GlaxoSmithKline plc (LON:GSK) Insider Acquires £127.44 in Stock

Share on StockTwits

GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley bought 8 shares of the company’s stock in a transaction dated Thursday, August 9th. The shares were acquired at an average cost of GBX 1,593 ($20.55) per share, with a total value of £127.44 ($164.40).

LON:GSK traded down GBX 13 ($0.17) during mid-day trading on Tuesday, hitting GBX 1,571.60 ($20.27). The stock had a trading volume of 6,311,427 shares, compared to its average volume of 9,120,000. GlaxoSmithKline plc has a twelve month low of GBX 1,235.20 ($15.93) and a twelve month high of GBX 1,724.50 ($22.25).

The company also recently announced a dividend, which will be paid on Thursday, October 11th. Investors of record on Thursday, August 9th will be issued a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 9th. This represents a yield of 1.23%.

GSK has been the subject of several research analyst reports. Barclays set a GBX 1,750 ($22.57) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Monday, July 23rd. Shore Capital raised shares of GlaxoSmithKline from an “average” rating to a “buy” rating and set a GBX 41.74 ($0.54) target price for the company in a research note on Thursday, July 26th. Cfra set a GBX 1,550 ($19.99) target price on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Thursday, July 26th. Deutsche Bank set a GBX 1,525 ($19.67) target price on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday, July 31st. Finally, Goldman Sachs Group set a GBX 1,900 ($24.51) target price on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Monday, July 23rd. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,546.53 ($19.95).

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.